Serum Institute To Pause Vaccine Trials In India After Drug Controller’s Notice


Serum Institute of India, which is manufacturing the coronavirus vaccine Covishield being developed by the Oxford University along with pharma major AstraZenca, today said it will stop the Phrase 3 trials that were to begin in India next week. The vaccine trial was stopped across four nations as a precautionary measure after one of the recipients in the UK showed some potentially adverse symptoms.

The Serum Institute was issued a showcause by the country's drug controller DCGI yesterday, where it was questioned why it was continuing the trials in India even though it has been stopped elsewhere.

“We are reviewing the situation and pausing India trials till AstraZeneca restarts the trials,” read a statement from the Serum Institute, which was still doing the groundwork for the trial including listing volunteers.

See also  COVID patient with severe complications recovers after double ECMO at MGM Healthcare Chennai


Please enter your comment!
Please enter your name here